Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
Objective Systemic sclerosis (SSc) is a heterogeneous connective tissue disease that is typically subdivided into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) depending on the extent of skin involvement. This subclassification may not capture the entire variability of clinical phe...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 71; no. 9; pp. 1553 - 1570 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.09.2019
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
Systemic sclerosis (SSc) is a heterogeneous connective tissue disease that is typically subdivided into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) depending on the extent of skin involvement. This subclassification may not capture the entire variability of clinical phenotypes. The European Scleroderma Trials and Research (EUSTAR) database includes data on a prospective cohort of SSc patients from 122 European referral centers. This study was undertaken to perform a cluster analysis of EUSTAR data to distinguish and characterize homogeneous phenotypes without any a priori assumptions, and to examine survival among the clusters obtained.
Methods
A total of 11,318 patients were registered in the EUSTAR database, and 6,927 were included in the study. Twenty‐four clinical and serologic variables were used for clustering.
Results
Clustering analyses provided a first delineation of 2 clusters showing moderate stability. In an exploratory attempt, we further characterized 6 homogeneous groups that differed with regard to their clinical features, autoantibody profile, and mortality. Some groups resembled usual dcSSc or lcSSc prototypes, but others exhibited unique features, such as a majority of lcSSc patients with a high rate of visceral damage and antitopoisomerase antibodies. Prognosis varied among groups and the presence of organ damage markedly impacted survival regardless of cutaneous involvement.
Conclusion
Our findings suggest that restricting subsets of SSc patients to only those based on cutaneous involvement may not capture the complete heterogeneity of the disease. Organ damage and antibody profile should be taken into consideration when individuating homogeneous groups of patients with a distinct prognosis. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Drs. Sobanski and Giovannelli contributed equally to this work. Drs. Launay and Hachulla contributed equally to this work. 1Vincent Sobanski, MD, PhD, David Launay, MD, PhD, Eric Hachulla, MD, PhD: Univ. Lille, INSERM U995 LIRIC, CHU Lille, and Referral Center for Rare Systemic Autoimmune Diseases North and North‐West of France, Lille, France; 2Jonathan Giovannelli, MD, PhD: Univ. Lille, INSERM U995 LIRIC, and CHU Lille, Lille, France; 3Yannick Allanore, MD, PhD: Hôpital Cochin, AP‐HP, and Université Paris Descartes, Paris, France; 4Gabriela Riemekasten, MD, PhD: University Clinic Schleswig‐Holstein, University of Lübeck, Lübeck, Germany; 5Paolo Airò, MD, ASST: Spedali Civili di Brescia, Brescia, Italy; 6Serena Vettori, MD, PhD: Second University of Naples, Naples, Italy; 7Franco Cozzi, MD, PhD: University of Padua, Padua, Italy; 8Oliver Distler, MD, PhD: University Hospital Zurich, Zurich, Switzerland; 9Marco Matucci‐Cerinic, MD, PhD: Azienda Ospedaliero‐Universitaria Careggi, University of Florence, Florence, Italy; 10Christopher Denton, MD, PhD: Royal Free Hospital, University College London, London, UK. Dr. Sobanski has received consulting fees and speaking fees from Grifols (less than $10,000) and has received research support from Actelion, Grifols, GlaxoSmithKline, Octapharma, Pfizer, and Shire. Dr. Distler has received consulting fees and speaking fees from Actelion, Bayer, Biogen Idec, Boehringer Ingelheim, ChemomAb, EspeRare Foundation, Genentech, GlaxoSmithKline, Inventiva, Eli Lilly, Medac, MedImmune, Mitsubishi Tanabe Pharma, Pharmacyclics, Novartis, Pfizer, Sanofi, Sinoxa, UCB, and Roche (less than $10,000 each); has received research support from Actelion, Bayer, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, and Roche; and holds a patent for mir‐29 for the treatment of systemic sclerosis. Dr. Denton has received consulting fees and speaking fees from Actelion, Boehringer Ingelheim, Bayer, GlaxoSmithKline, Inventiva, Roche, and Sanofi‐Aventis (less than $10,000 each) and has received research support from Bayer, CSL Behring, GlaxoSmithKline, Inventiva, and Roche. Dr. Launay has received research support from Actelion, GlaxoSmithKline, Octapharma, Pfizer, and Shire. No other disclosures relevant to this article were reported. Data are available from the European Scleroderma Trials and Research database upon request. |
ISSN: | 2326-5191 2326-5205 2326-5205 |
DOI: | 10.1002/art.40906 |